Acknowledgements
RARE DISEASE
Writing assistance was provided by Vikte Lionikaite, PhD, Stephen McKenna, MSc, and Rebecca Hornby, PhD, of Oxford PharmaGenesis, Oxford, UK, with funding from Alexion, AstraZeneca Rare Disease.